Printer Friendly

DURAMED AND SCHEIN COMPLETE AGREEMENT FOR CONJUGATED ESTROGENS DEVELOPMENT

 DURAMED AND SCHEIN COMPLETE AGREEMENT FOR
 CONJUGATED ESTROGENS DEVELOPMENT
 CINCINNATI, June 29 /PRNewswire/ -- E. Thomas Arington, chairman and president of Duramed Pharmaceuticals, Inc. (NASDAQ: DRMD), and Martin Sperber, chairman of Schein Pharmaceutical Inc., today announced the signing of the definitive agreement for the development, manufacturing and marketing of a new formulation of Conjugated Estrogens Tablets, the generic equivalent to the brand product Premarin. This agreement is pursuant to the letter of intent announced on March 2, 1992. This new formulation is being designed to meet bioequivalence guidance established by the Food and Drug Administration (FDA) in late 1991.
 Under the agreement, Schein will provide project funding and technical assistance while Duramed will be responsible for product development and manufacturing. Both firms will participate in the marketing and distribution of the Conjugated Estrogens products after receiving FDA approval. An application for such approval will be submitted after successful completion of bioequivalence testing.
 Schein Pharmaceutical is a leading manufacturer of pharmaceuticals and the only U.S. multisource company with extensive capabilities for the production of oral solid, parenteral and ophthalmic dosage forms. Schein, through its manufacturing operations, Danbury Pharmacal and Steris Laboratories, manufactures more than 425 pharmaceutical products, more than any other multisource company.
 Duramed Pharmaceuticals, Inc. manufactures and sells generic drug products composed of various dosages of prescription and over-the- counter drugs. Duramed's stock is traded under the symbol DRMD.
 -0- 6/29/92
 /CONTACT: E. Thomas Arington, chairman and president; or Timothy J. Holt, vice president-finance, both of Duramed Pharmaceuticals, Inc., 513-731-9900/
 (DRMD) CO: Duramed Pharmaceuticals, Inc.; Schein Pharmaceutical Inc. ST: Ohio IN: MTC SU: JVN


KK -- CL003 -- 4564 06/29/92 09:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1992
Words:275
Previous Article:MCI VISION OFFERS BUSINESSES COMPREHENSIVE LONG DISTANCE SERVICE FOR ALL CALLING NEEDS
Next Article:RALPHS GROCERY EXTENDS DEBENTURE TENDER OFFER TO JULY 6
Topics:


Related Articles
DURAMED AND SCHEIN SIGN LETTER OF INTENT FOR CONJUGATED ESTROGENS DEVELOPMENT
DURAMED REPORTS FIRST QUARTER RESULTS FOR 1995
DURAMED REPORTS SECOND QUARTER RESULTS FOR 1995
DURAMED OPTIMISTIC AFTER FDA ADVISORY COMMITTEE MEETING ON CONJUGATED ESTROGENS
Duramed Pharmaceuticals Reports Third Quarter 1996 Results
Duramed Pharmaceuticals Partners with Cardinal Health and Cardinal MarketFORCE for Distribution and Sales of Cenestin.
Duramed Pharmaceuticals Completes Stock Sale to Solvay Pharmaceuticals Announces Settlement with Schein Pharmaceutical.
Duramed Pharmaceuticals Reports Third Quarter Results.
Duramed Expands Marketing Alliance with Solvay Pharmaceuticals, Inc.
MIICRO, Inc. Signs Agreement with Duramed Pharmaceuticals, Inc. to Evaluate CNS Effects of Cenestin(R) and Prometrium(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters